InvestorsObserver
Sign Up Login

AGLE Aeglea Biothera

$1.55 $0.05 (3.33%)
Add to Watchlist Compare
Overall

AGLE Stock Analysis Overview

What this means: InvestorsObserver gives Aeglea Biothera (AGLE) an overall rank of 30, which is below average. Aeglea Biothera is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 30 means that 70% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

AGLE Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

AGLE Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

AGLE Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

AGLE Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

AGLE Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

AGLE Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

AGLE Stock Analysis Overview

What this means: InvestorsObserver gives Aeglea Biothera (AGLE) an overall rank of 30, which is below average. Aeglea Biothera is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 30 means that 70% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full AGLE report

AGLE Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

AGLE Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

AGLE Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

AGLE Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

AGLE Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

AGLE Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Aeglea Biothera (AGLE) Analyst Forecast

AGLE Price, Volume, Earnings, and Dividend Date

  • Last Price $1.55
  • Previous Close $1.50
  • Change $0.05
  • Open $1.50
  • Volume 145,796
  • Avg. Volume (100-day) 481,957
  • Market Cap 94,817,391
  • Days Range 1.43 - 1.58
  • 52-week Range 1.29 - 8.5
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 08/03/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 1.204
  • PEG Ratio —

Aeglea Biothera (AGLE) Company Description

Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.

Aeglea Biothera (AGLE) Stock Chart

View Interactive AGLE chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Point Biopharma Global Inc (PNT) (PNT) $7.91
Catalyst Bio (CBIO) (CBIO) $1.11
Concert Pharmaceutic (CNCE) (CNCE) $5.02
SC Pharmaceuticals Inc (SCPH) (SCPH) $4.90
Veru Inc (VERU) (VERU) $12.64
Mirum Pharmaceuticals Inc (MIRM) (MIRM) $24.58
Adma Biologics (ADMA) (ADMA) $1.94
Fennec Pharmaceuticals Inc (FENC) (FENC) $5.78
Tricida Inc (TCDA) (TCDA) $8.08
Vaxcyte Inc (PCVX) (PCVX) $25.86